Digital Content 
NEWS #PharmaBuzz
01 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology-302470143.html
22 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/22/3087169/0/en/Cullinan-Therapeutics-Taiho-Pharmaceutical-and-Taiho-Oncology-to-Present-Positive-Results-from-Pivotal-Phase-2b-REZILIENT1-Trial-of-Zipalertinib-at-ASCO-2025.html
23 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/23/3066564/0/en/Cullinan-Therapeutics-to-Present-Results-from-REZILIENT1-a-Phase-1-2-Trial-of-Zipalertinib-in-Patients-with-Non-Small-Cell-Lung-Cancer-Harboring-EGFR-Exon-20-Insertion-Mutations-Wh.html
28 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-receiv-302362492.html
01 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/01/2891804/0/en/Cullinan-Therapeutics-Announces-Positive-Initial-Data-from-Pivotal-Phase-2b-REZILIENT1-Study-of-Zipalertinib.html
03 Aug 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rezilient3-global-first-line-trial-of-zipalertinib-launched-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-301893051.html
Share 